ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells

about

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells

Item

http://www.wikidata.org/entity/Q58699999

description

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@en

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@nl

type

Item

label

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@en

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@nl

prefLabel

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@en

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@nl

P1476

ISL1 promotes cancer progressi ...... e-negative breast cancer cells

@en

P2093

Haifeng Cai

http://www.w3.org/2001/XMLSchema#string

Hao Dai

http://www.w3.org/2001/XMLSchema#string

Jian Sun

http://www.w3.org/2001/XMLSchema#string

Jianglun Shen

http://www.w3.org/2001/XMLSchema#string

Lu Wang

http://www.w3.org/2001/XMLSchema#string

Ning Li

http://www.w3.org/2001/XMLSchema#string

Peng Gao

http://www.w3.org/2001/XMLSchema#string

Yang Zhang

http://www.w3.org/2001/XMLSchema#string

Yanqin Lu

http://www.w3.org/2001/XMLSchema#string

Yiming Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells.

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

P304

2343-2352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJMM.2018.3842

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30226569

http://www.w3.org/2001/XMLSchema#string

P932

6192754

http://www.w3.org/2001/XMLSchema#string